Universität zu Köln

Buettner, R., Wolf, J. and Kron, A. (2019). The national Network Genomic Medicine (nNGM). Model for innovative diagnostics and therapy of lung cancer within a public healthcare system. Pathologe, 40 (3). S. 276 - 281. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Full text not available from this repository.

Abstract

BackgroundSince 2012, the Network Genomic Medicine (NGM) has been providing alarge number of lung cancer patients from referring partner sites with comprehensive molecular-pathological diagnostics on the single diagnostic platform at the University Hospital Cologne. In addition, the network headquarters in Cologne interprets the findings in close interdisciplinary coordination between pathologists and oncologists, provides information on innovative treatment options, and evaluates the personalized therapies using the central database. As part of one of its largest single grants in 2018, the German Cancer Aid (DKH) rolled out this interdisciplinary and intersectoral care model to all existing DKH-funded German comprehensive cancer centers at the time of the initial application.GoalPresentation of the treatment reality within the national Network Genomic Medicine (nNGM) with its core elements and actors (network centers and intersectoral clinical partners sites).MethodsThis article is based on our own experience in NGM and nNGM and includes asummary of the currently applicable guidelines for reimbursement and an overview of the treatment landscape in the field of molecular-pathological diagnostics in Germany.ResultsThe focus of nNGM is on the implementation of innovative molecular diagnostics and personalized therapy in broad clinical routine in Germany. This is enabled by developing molecular-pathological diagnostics within the network centers on an ongoing basic, interdisciplinary counseling of referring partner sites, offering innovative clinical trials, and performing central evaluation. In particular, afocus of nNGM is the development of regional networks to treat the affected lung cancer patients close to home at the partner sites whenever possible.DiscussionInterdisciplinary teams are essential for the success of abroad implementation of molecular-pathological diagnostics. nNGM addresses asevere deficit in German lung cancer care and in the future will be expanded to further network centers while meeting the defined quality criteria.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Buettner, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolf, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kron, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-149320
DOI:	10.1007/s00292-019-0605-4
Journal or Publication Title:	Pathologe
Volume:	40
Number:	3
Page Range:	S. 276 - 281
Date:	2019
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-1963
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Pathology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14932